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Abstract
Zoledronate (Zol) is a third-generation bisphosphonate that is widely used as an anti-resorptive 
agent for the treatment of cancer bone metastasis. While there is preclinical data indicating that 
bisphosphonates such as Zol have direct cytotoxic effects on cancer cells, such effect has not been 
firmly established in the clinical setting. This is likely due to the rapid absorption of 
bisphosphonates by the skeleton after intravenous (i.v.) administration. Herein, we report the 
reformulation of Zol using nanotechnology and evaluation of a novel nanoscale metal-organic 
frameworks (nMOFs) formulation of Zol as an anticancer agent. The nMOF formulation is 
comprised of a calcium zoledronate (CaZol) core and a polyethylene glycol (PEG) surface. To 
preferentially deliver CaZol nMOFs to tumors as well as facilitate cellular uptake of Zol, we 
incorporated folate (Fol)-targeted ligands on the nMOFs. The folate receptor (FR) is known to be 
overexpressed in several tumor types, including head-and-neck, prostate, and non-small cell lung 
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cancers. We demonstrated that these targeted CaZol nMOFs possess excellent chemical and 
colloidal stability in physiological conditions. The release of encapsulated Zol from the nMOFs 
occurs in the mid-endosomes during nMOF endocytosis. In vitro toxicity studies demonstrated 
that Fol-targeted CaZol nMOFs are more efficient than small molecule Zol in inhibiting cell 
proliferation and inducing apoptosis in FR-overexpressing H460 non-small cell lung and PC3 
prostate cancer cells. Our findings were further validated in vivo using mouse xenograft models of 
H460 and PC3. We demonstrated that Fol-targeted CaZol nMOFs are effective anticancer agents 
and increase the direct antitumor activity of Zol by 80 to 85% in vivo through inhibition of tumor 
neovasculature, and inhibiting cell proliferation and inducing apoptosis.
Graphical abstract
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1. Introduction
Zoledronate (Zol) is a third-generation nitrogen-heterocycle-containing bisphosphonate 
[1-9]. It is widely used as an anti-resorptive agent to prevent cancer metastases in bones 
[1-9]. Unlike the first-generation bisphosphonates (e.g. etidronate), Zol inhibits bone 
resorption by directly inhibiting farnesyl diphosphate synthase (FPPS), a key enzyme of the 
mevalonate pathway. The inhibition of FPPS suppresses geranylation and farnesylation of 
several key proteins, which in turn activates the production of cell signaling molecules to 
stop osteoclastic activities [1-9]. Interestingly, in vitro studies also demonstrated that FPPS 
inhibition can decrease cell proliferation and migration, as well as induce apoptosis [1, 10]. 
In addition, a number of in vitro and clinical studies demonstrated that Zol efficiently 
inhibits basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(VEGF) signaling, thus inhibiting blood vessel growth in a tumor [11, 12]. A recent clinical 
trial in early-stage breast cancer patients showed that adjuvant bisphosphonate treatment 
reduced not only the chance of cancer metastasis in bones, but also reduced the probability 
of getting secondary cancers [13], which could be related to the direct cytotoxic effects of 
Zol [5]. However, clinical translation of Zol as a cytotoxic agent is challenging. Small-
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molecule Zol has a short circulation half-life (105 min), and its maximum plasma 
concentration is only about 1 μM (10 - 100 times lower than that required to kill cancer cells 
in vitro) at recommended dosing [9]. Biodistribution studies indicated that about 55% of 
i.v.-administrated Zol is rapidly taken up by the skeleton and that the remaining Zol 
undergoes renal clearance without metabolism [9]. Therefore, high concentrations of Zol is 
difficult to achieve due to its toxicity.
One strategy to enable the use of Zol as a cytotoxic agent is to utilize nanoscale 
metaloragnic framework (nMOF) drug delivery. nMOF drug-delivery systems can enhance 
Zol's biodistribution to tumors and potentially improve its direct anticancer effect [14-17]. 
Previous reports using liposomes to deliver Zol did indeed show improved pharmacokinetics 
and biodistribution [16]. However, the drug loading of these Zol-encapsulated liposomes are 
relatively low (< 10 wt%) [16]. In addition, Zol-encapsulated liposomes only showed 
moderated antitumor activity in various tumor xenograft models [14-16]. Therefore, we 
aimed to develop a novel and more effective nMOF formulation of Zol that can be utilized 
as a cytotoxic agent.
Herein, we reported the fabrication of a new bioresorbable sub-100nm diameter pH-
responsive calcium zoledronate (CaZol) nMOF as a potential cytotoxic anticancer agent. We 
incorporated a targeting ligand, folate (Fol), to facilitate tumor uptake of the CaZol nMOFs 
because the folate receptor (FR) is frequently overexpressed on tumors. More than two 
thirds of head-and-neck cancer, prostate cancer, and small and non-small cell lung cancer 
(SNSCLC) upregulate FR [18]. The cellular uptake and intracellular Zol release mechanisms 
of these new actively targeted lipid-coated nMOFs have been investigated. The direct 
anticancer activities (e.g., the ability to inhibit cell proliferation, and the ability to induce 
cell apoptosis) of small-molecule Zol, non-targeted CaZol nMOFs and Fol-targeted CaZol 
nMOFs were compared using fast-growing H460 NSCLC and slowing-growing PC3 
prostate cancer cell lines [18-20]. The tumor uptake and biodistribution of the Fol-targeted 
and non-targeted CaZol nMOFs have been investigated in xenograft tumor-bearing mice. 
Finally, the direct anticancer activities of small-molecule Zol, non-targeted, and Fol-targeted 
CaZol nMOFs were quantitatively investigated in H460 and PC3 xenograft tumor murine 
models. Further histopathological studies were performed to investigate the mechanism 
action of these novel CaZol nMOFs.
2. Materials and Methods
2.1. Materials
Calcium chloride dihydrate (ReagentPlus, ≥ 99.0%), zoledronic acid monohydrate (≥98%), 
sodium hydroxide (BioXtra, ≥ 98%), cyclohexane (ACS reagent, ≥ 99%), 1-hexanol 
(anhydrous, > 99%), Triton X-100 (BioXtra), Igepal CO-520, ethanol (ACS reagent, 200 
proof, ≥ 99.5%), chloroform (ACS agent, ≥ 99.8%), and Fura-2 pentakis(acetoxymethyl) 
ester (Fura-2AM) were purchased from Sigma-Aldrich (St. Louis, MO). 
Dioleoylphosphatydic acid (DOPA); 1,2-dioleoyl-3-trimethylammonium-propane 
(DOTAP); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[folate(polyethylene 
glycol)-2000] (DSPE-PEG2000-Folate); 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-[poly(ethylene glycol)2000] (DSPE-PEG 2000); 25-[N-[ (7-nitro-2-1,3-benzoxadiazol-4-
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yl)methyl]amino]-27-norcholesterol (NBD-labeled cholesterol); and cholesterol were 
purchased from Avanti Polar Lipids, Inc. (Alabaster, AL). Double-deionized (HPLC grade, 
sub-micron filtered) were purchased from Fischer Scientific (Hampton, NH). Dulbeco's 
phosphate buffer saline (0.1 M, PBS) was purchased from Gibco by Life Technologies 
(Carlsbad, CA).
2.2. Characterization
2.2.1. nMOF Characterization
2.2.1.1. Transmission Electron Microscopy: TEM images were recorded using a Zeiss 
TEM 910 Transmission Electron Microscope operated at 80 kV (Carl Zeiss Microscopy, 
LLC, Thornwood, NY) in Microscopy Services Laboratory Core Facility at the UNC School 
of Medicine. Prior to TEM imaging, concentrated nMOF samples were diluted with 
chloroform (for the hydrophobic DOPA-coated CaZol nMOFs) or deionized water for the 
hydrophilic CaZol nMOFs and Fol-targeted liposomes. 5 μL of each diluted sample was 
mixed with 5 μL of 4 % uranyl acetate aqueous solution before being added to a 400 mesh 
carbon filmed copper grid via a pipette. Excess nMOF dispersion was removed by filter 
paper at the edge of copper grid. For the liposome sample, diluted liposomes (5 μL) were 
mixed with 50 μL of 4 % uranyl acetate aqueous solution before being added to a 400 mesh 
carbon filmed copper grid via a pipette. Excess nMOF dispersion was removed by filter 
paper at the edge of copper grid. The recorded TEM images were processed using ImageJ 
(NIH). Number-average diameter (Dn) was determined based on the average diameter of at 
least 150 particles from a representative TEM image.
2.2.1.2. Nanoparticle Trackling Analysis: The mean number-average diameter (Dn) and 
particle concentrations of hydrophilic CaZol nMOFs and liposomes were determined by a 
nMOF-tracking analysis method recorded on a Nanosight NS500 instrument (Malvern, Inc.).
2.2.1.3. Dynamic Light Scattering and Aqueous Electrophoresis Studies: All nMOF 
dispersions were diluted to 5 μg/mL prior to the nMOF tracking analysis. Intensity-average 
diameter (Dh, also known as hydrodynamic diameter) and mean zeta potential (mean ζ) of 
nMOF dispersions were determined by dynamic light scattering and an aqueous 
electrophoresis method using a Zetasizer Nano ZS Instrument (Malvern, Inc.). All 
measurements were based on the average of 3 separate measurements.
2.2.1.4. Thermogravimetric Analysis: Thermogravimetric analysis (TGA) was performed 
in a TA Instrument Q500 Thermogravimetric Analyzer. The analysis was performed from 
20 to 800 °C operated at a heating rate of 20 °C per min in air during which the sample was 
equilibrated at 100 °C for 10 min prior heat up to 800 °C. This avoid the residual moisture 
interfere the measurement.
2.2.1.5. Infrared spectroscopy: Infrared spectroscopy was conducted using a Nicolet iS10 
FT-IR spectrometer equipped with an Attenuated Total Reflectance (ATR) accessory in 
Nanomedicines Characterization Core Facility in the School of Medicine at the UNC School 
of Medicine. The spectral resolution was 4 cm-1 and 128 scans were averaged per spectrum.
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2.2.1.6. Energy-dispersive X-ray spectroscopy: Energy-dispersive X-ray spectroscopy 
(EDS) was performed in a Hitachi S-4700 Field Emission Scanning Electron Microscopy 
(FE SEM) equipped with an Oxford instruments, INCA PentaFET x3 EDS detector in 
Analytical and Nanofabrication Laboratory in the Department of Chemistry at the University 
of North Carolina at Chapel Hill. The sample was prepared by drying a drop of sample onto 
a carbon tape on a SEM copper grid. FE SEM was conducted at 15 kV.
2.2.1.7. X-ray photoelectron spectroscopy: X-ray photoelectron spectroscopy (XPS) was 
performed by drying a dilute nMOF sample onto a silicon wafer at room temperature. XPS 
analysis was conducted using Kratos Axis Ultra DLD X-ray Photoelectron Spectrometer in 
Analytical and Nanofabrication Laboratory in the Department of Chemistry at the University 
of North Carolina at Chapel Hill. The XPS spectrometer was equipped with a 
monochromatic Al X-ray source operating at 6 mA and 15 kV at less than 10-8 torr. The step 
size was 0.5 eV for the survey spectra (pass energy = 160 eV) and 0.05 eV for high-
resolution core-line spectra (pass energy = 80 eV).
2.2.1.8. X-ray Powder Diffraction: X-ray powder diffraction spectrum of dried nMOF 
sample was recorded using a Rigaku Multiflex Powder Diffractometer in the X-Ray Facility 
in the Department of Chemistry at the University of North Carolina at Chapel Hill.
2.2.2. Solid content and drug loading determination—The solid content of the 
DOPA-coated CaZol nMOF dispersion (dispersed in chloroform) was determined by the 
gravimetric method. Zol loading in the DOPA-coated CaZol nMOFs was determined by a 
well-documented ultraviolet-visible spectroscopic method. Briefly, 100 μL of the nMOF 
dispersion with a known weight was dried in a pre-weighted glass vial under a vacuum for 
12 h. The solid content of the nMOF dispersion was determined by comparing the weight of 
the dried vial containing the dried nMOFs and the weight of an empty vial. The dried 
nMOFs were digested with 500 μL of 0.2 M hydrochloric acid at 20 °C for 24 h. The 
concentration of Zol in the solution was determined by comparing the absorbance at 215 nm 
with that of 5 different Zol standards in 0.2 M hydrochloric acid.[17]
Zol loading in the PEGylated lipid-coated nMOF aqueous dispersion was determined using 
a similar spectroscopic method. Briefly, 100 μL of the nMOF dispersion (with known 
weight) was freeze-dried in a pre-weighted glass vial. The solid content of the nMOF 
dispersion was determined by comparing the weight of the dried vial containing the dried 
nMOFs to the weight of an empty vial. The dried nMOFs were digested with 250 μL of 0.4 
M hydrochloric acid at 20 °C for 24 h and mixed with 250 μL of ethanol prior to 
spectroscopic measurements. The concentration of Zol in the solution was determined by 
comparing the absorbance at 215 nm with that of 5 different Zol standards in 0.2 M HCl 
(with 50% ethanol by volume).[17]
2.3. Synthesis
2.3.1. Preparation of hydrophobic DOPA-coated CaZol nMOFs—Hydrophobic 
DOPA-coated CaZol nMOFs were prepared using the water-in-oil reverse microemulsion 
method. Sodium zoledronate was prepared in situ by dissolving zoledronate in a NaOH 
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aqueous solution containing the equivalent of 4 moles of NaOH. Bisphosphonate- and 
calcium-based microemulsions were first prepared. The bisphosphonate-based 
microemulsion was prepared by mixing (at 800 rpm) 1 mL of 50 mM Zol (in 200 mM 
NaOH) with 80 mL of a desired oil phase containing 3.2 mL of 20 mM DOPA (in 
chloroform) at 20 °C for 30 min. The calcium-based microemulsion was prepared by mixing 
(at 800 rpm) 1 mL of 500 mM CaCl2 solution with 80 mL of the desired oil phase at 20 °C 
for 30 min. The two microemulsions were combined and stirred (at 800 rpm) at 20 °C for 
another 30 min, and 160 mL of ethanol was added and stirred at 20 °C for another 20 min to 
break the emulsion. The resulting dispersion was purified by centrifugation (at 4,500 g for 3 
h) and redispersion. At the end of each cycle, the pallets were redispersed in a minimum 
amount of chloroform and precipitated into an excess amount of ethanol. The centrifugation-
redispersion cycle was repeated another 4 times. At the end of the purification cycle, the 
pallets were resuspended into 5 mL of chloroform. The organic dispersion was centrifuged 
at 2,000 g for 5 min to remove CaZol NMOFs and aggregated NMOFs that were not fully 
DOPA-coated. The supernatant containing well-dispersed, DOPA-coated CaZol NMOFs 
were stored at −20 °C before further use.
[Note: The oil phases used in the preparation of the DOPA-coated CaZol nMOFs were 
based on different volume ratios (1:0, 2:1, 1:1, 1:2, 0:1 v/v) of the Igepal CO-520-based and 
the Triton X-100-based oils. The Igepal CO-520-based oil contains 71:29 v/v of 
cyclohexane and Igepal CO-520 (as surfactant). The Triton X-100-based oil contains 
75:15:10 v/v/v of cyclohexane, Triton X-100 (surfactant) and 1-hexanol (co-surfactant).]
2.3.2. Fabrication of active-targeted lipid coating (outer lipid leaflet) onto 
DOPA-coated CaZol nMOFs—The active-targeted outer lipid leaflet was fabricated onto 
the hydrophobic DOPA-coated CaZol nMOFs via an optimized film rehydration method. To 
create the outer leaflet, 1mL of the DOPA-coated CaZol nMOFs was mixed with 400 μL of 
20 mM cholesterol, 400 μL of 20 mM DOTAP and 200 μL of Fol-targeted DSPE-PEG2000. 
The mixture was dried in a vacuum at 20 °C for 18 h. The resulting film was rehydrated with 
2 mL of warm deionized water (90 °C) via bath-type sonication (5 min) to facilitate the self-
assembly of the outer lipid leaflet. The nMOFs were purified by ultrafiltration (4 times at 
3,000 g for 15 min) using an Amicron Ultra ultrafiltration membrane filter with a 100,000 
nominal molecular weight cutoff to remove excess lipids.
Non-targeted CaZol nMOFs were prepared using an identical method, except a non-targeted 
DSPE-PEG2000 was used instead of a Fol-targeted DSPE-PEG2000. Similarly, fluorescent 
NBD-labeled CaZol nMOFs were prepared using NBD-labeled cholesterol instead of non-
labeled cholesterol.
2.3.3. Synthesis of bulk CaZol MOFs—Bulk CaZol MOFs were synthesized using 
hydrothermal synthesis method, as previous reported [17].
2.3.4. Synthesis of drug-free Fol-targeted liposomes—Drug-free Fol-targeted 
liposomes were prepared using the as mentioned film rehydration method in the absence of 
DOPA-coated CaZol nMOFs. Briefly, 400 μL of 20 mM cholesterol, 400 μL of 20 mM 
DOTAP and 200 μL of Fol-targeted DSPE-PEG2000 were mixed and dried under vacuum at 
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20 °C for 18 h. The resulting film was rehydrated with 2 mL of warm deionized water (90 
°C) via bath-type sonication (5 min) to facilitate the self-assembly of the outer lipid leaflet. 
The drug-free liposomes were used without further purification.
2.4. Drug release studies
2.4.1. In vitro drug release study—The in vitro drug-release profiles of Fol-targeted 
CaZol nMOFs were recorded under sink conditions. nMOF solutions at a concentration of 
50 μg/mL were split into Slide-A-Lyzer MINI dialysis microtubes (Pierce, Rockford, IL) 
with a molecular cutoff of 10 kDa and subjected to dialysis against large excess of 
phosphate buffer saline (500 μL of nMOF dispersion per 1 L of 0.1 M PBS) with gentle 
stirring at 37 °C. The pH was either 7 or 5. At the indicated time, 20 μL of the solution was 
removed from the microtubes and digested with 20 μL 0.8 M HCl at 20 °C for 24 h and 
mixed with 40 μL ethanol prior to the spectroscopic measurement. The concentration of Zol 
in the solution was determined by comparing the absorbance at 215 nm with that of 5 
different Zol standards in 0.2 M HCl in 0.1 M PBS (with 50% ethanol by volume). All 
measurements were performed in triplicate.
2.4.2. Intercellular drug release study—A total of 1 × 104 cells of H460 or PC3 cells 
in complete culture media (free of phenol red) were plated separately in 8-well culture slides 
(Fischer) at 37 °C for 24 h before the intercellular drug-release study. The cells were first 
washed 3 times with PBS before being incubated with diluted Fura-2AM (1 mM of 
Fura-2AM in DMSO was diluted 200-fold into PBS) at 37 °C for 1 h. The cells were washed 
3 times with PBS to remove excess Fura-2AM. The Fura-2-loaded cells were treated with 
Fol-targeted CaZol nMOFs containing 5 μM encapsulated Zol or PBS (control) at 37 °C. 
After the desired incubation period (t = 0 min, 30 min or 2 h), the cells were washed 3 times 
with PBS and fixed with 4% (by volume) neutral-buffered formalin. Fluorescein images 
were recorded at an excitation wavelength of 362 nm and emission wavelength of 512 nm 
(the red channel, which is proportional to the amount of free Fura-2 inside the cells), and an 
excitation wavelength of 362 nm and emission wavelength of 512 nm (the green channel, 
which is proportional to the amount of Fura-2-Ca complex formed due to the Ca2+ released 
from the CaZol nMOFs). The fluorescence intensity recorded at each channel was quantified 
using ImageJ (NIH).
2.5. In vitro studies
2.5.1. Cell Culture—H460 non-small lung cancer cells and PC3 prostate cancer cells were 
obtained from American Type Culture Collection (ATCC). H460 cells were cultured using 
RPMI-1640 medium supplemented with 10 % (v/v) FBS, 2 mM glutamine, 1.5 g/L sodium 
bicarbonate, 10 mM HEPES buffer (Corning), 1 mM sodium pyruvate, 1 % (v/v) penicillin/
streptomycin and 4.5 g/L glucose (Sigma). PC3 cells were cultured in a 1:1 mixture of 
DMEM and Ham's F-12 medium (Gibco) supplemented with 10 % (v/v) FBS and 1 % (v/v) 
penicillin/streptomycin (Sigma). The cell density of trypsinized cancer cells were 
determined by an Orflo Moxi Z Mini Automated Cell Counter (Orflo, Ketchum, ID). Phenol 
red-free culture media were used in all fluorescent imaging studies.
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2.5.2. In vitro cellular uptake study—A total of 1 × 104 H460 or PC3 cells were plated 
in a 96-well fluorescent imaging plate (Greiner) for 24 h prior to the application of NBD-
labeled non-targeted or Fol-targeted CaZol nMOFs containing 5 μM of encapsulated Zol.‖ ‖ 
At the desired time, the nMOFs were removed, washed 3 times with PBS, and fixed with 4% 
(by volume) of neutral-buffered formalin. The uptake of Rhod-labeled PEG-PLGA nMOFs 
was determined via a 96-well plate reader (Infinite® 200 Pro, Tecan i-control) using an 
excitation wavelength of 485 nm and an emission wavelength of 535 nm. The fluorescent 
imaging study was performed in an 8-well culture slide (Fischer). A total of 1 × 104 H460 or 
PC3 cells were plated in an 8-well culture slide (Fischer) for 24 h prior to the application of 
NBD-labeled Fol-targeted or non-targeted CaZol nMOFs containing 5 μM of encapsulated 
Zol (100 μL per well). After being incubated for 30 min, the nMOFs were removed, washed 
3 times with PBS, and fixed with 4% (by volume) of neutral-buffered formalin, then 4′,6-
diamidino-2phenylindole (DAPI/Antifade solution; EHD Millipore, Billerica, MA) was 
added to label the nucleus. The cell culture slide was imaged on a Zeiss 710 Spectral CLSM 
in the Microscopy Services Laboratory Core Facility at the UNC School of Medicine.
2.5.3. In Vitro Cytotoxicity Studies
2.5.3.1. MTS Cell Proliferation Assay: In vitro toxicities of small-molecule and 
encapsulated Zol were evaluated using a cell viability assay. In a 96-well plate, 1 × 104 
H460 or PC3 cells were plated 24 h prior to treatment with drug-free Fol-targeted liposomes, 
small-molecule Zol, non-targeted CaZol nMOFs, and Fol-targeted CaZol nMOFs. Cancer 
cells were treated with different concentrations of small-molecule or nanoformulation Zol at 
37 °C for 2 h. The cells were washed with PBS and allowed to grow in complete cell culture 
media for 72 h. Cell viability (proliferation) was then analyzed using a 23-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium 
(MTS) assay according to manufacturer (Promega) instructions. The absorbance at 492 nm 
(which directly reflects cell viability) was recorded using a 96-well plate reader (Infinite® 
200 Pro, Tecan i-control).
2.5.3.2. Early-Stage Apoptosis Assay: Early-stage apoptosis (programmed cell death) in 
H460 and PC3 cells after in vitro treatment with PBS (control), small-molecule Zol, non-
targeted CaZol nMOFs, Fol-targeted CaZol nMOFs was quantified using rhodamine-B-
labeled caspase 3 (active) antibodies (Abcam, MA). A total of 1 × 104 H460 or PC3 cells 
were plated in an 8-well culture slide (Fischer) for 24 h prior to the application of PBS 
(control), 5 μM of small-molecule Zol, NBD-labeled Fol-targeted or non-targeted CaZol 
nMOFs containing 5 μM of encapsulated Zol (100 μL per well) for 2 h. The cells were 
washed 3 times with PBS and incubated with complete culture media (free of phenol red) at 
37 °C for 12 h before staining with the Rhod-B-labeled caspase 3 antibody according to 
manufacturer instructions. The stained cells were imaged on a Zeiss 710 Spectral CLSM in 
the Microscopy Services Laboratory Core Facility at the UNC School of Medicine.
2.6. In vivo studies
2.6.1. Drug dosing calculation—Zol is a well-established chemotherapy drug. The 
MTD of Zol in humans was found to be 0.13 mg/kg (8 mg for a 60-kg adult) [21, 22]. The 
MTD of Zol in mice was estimated using the MTD of Zol in humans and the well-
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documented human-to-mouse drug dosage conversion factor (12) [23]. Thus, the MTD of 
Zol in mice is equal to the human-to-mouse dosage conversion factor times the MTD of Zol 
in human (12 × 0.13 mg/kg ≈ 1.6 mg/kg). The calculated MTD of Zol in mice is 
comparable with previous in vivo toxicity studies performed with tumor-free mice.
2.6.2. In Vivo Tumor Uptake and Biodistribution Study—The tumor uptake and 
biodistribution of i.v. administered, NBD-labeled CaZol nMOFs were determined by the 
standard ex vivo fluorescence imaging method. Xenograft tumors were inoculated in the left 
flank of male athymic nude mice (6–7 weeks old, 29–30 g; UNC Animal Services Core, 
Chapel Hill, NC) by subcutaneous injection of 1 × 106 H460 or PC3 cells in 200 μL of a 1:1 
(by volume) mixture of serum-free RPMI-1640 (for H460 cells) or a 1:1 mixture of DMEM 
and Ham's F-12 medium/Matrigel solution. Either 10 (for H460 xenograft tumor-bearing 
mice) or 14 (for PC3 xenograft tumor-bearing mice) days after tumor inoculation, each 
mouse was given a tail-vein i.v. injection of NBD-labeled non-targeted CaZol nMOFs or 
NBD-labeled Fol-targeted CaZol nMOFs containing 1.6 mg/kg of encapsulated Zol. After 
48 h, all mice were euthanized by overdose of carbon dioxide. The xenograft tumor, liver, 
kidney, spleen, heart, and lung were immediately preserved for an ex vivo biodistribution 
study via IVIS Kinetic Imaging System equipped with an excitation filter of 465 nm and an 
emission filter of 535 nm in Small Animal Imaging Facility at UNC School of Medicine. All 
imaging parameters were kept constant for the whole imaging study. Region-of-interest 
values were recorded using Living Image software as photon flux (also known as radiance) 
in total photon count per centimeter-squared per steradian (p s-1 cm-2 Sr-1). In the control 
study, tumor-free Nu mice were given a tail-vein i.v. injection of NBD-labeled Fol-targeted 
CaZol nMOFs containing 1.6 mg/kg of encapsulated Zol. After 48 h, all mice were 
euthanized, and the xenograft tumor, liver, kidney, spleen, heart, and lung were immediately 
preserved in the same manner.
2.6.3. In Vivo Toxicity Study—The in vivo toxicity of small-molecule and encapsulated 
Zol were evaluated in healthy, tumor-free CD1 mice. In the in vivo study, 10-week-old male 
CD1 mice (Charles River Laboratory, Durham, NC) were given a tail-vein i.v. injection with 
200 μL PBS, drug-free Fol-targeted liposomes, 1.6 mg/kg of small-molecule Zol, or either 
non-targeted CaZol nMOFs or Fol-targeted CaZol nMOFs containing 1.6 mg/kg of 
encapsulated Zol. Four days after i.v. injection, each mouse was anesthetized via 
subcutaneous injection of 100 μL of ketamine hydrochloride/xylazine hydrochloride solution 
(Sigma; St. Louis, MO). Circulating blood (about 0.6 mL) was collected directly from the 
heart; 100 μL of each whole-blood sample was stored in an EDTA-coated tube at 5 °C prior 
to the blood toxicity study in the Animal Clinical Laboratory Core Facility at the UNC 
Medical School. A 400-μL portion of each whole-blood sample was transferred to a 
microcentrifuge tube and stored at room temperature for 20 min before being centrifuged at 
3,000 g for 5 min to separate the red blood cells from the plasma. The isolated plasma was 
stored at 5 °C before being submitted to the Animal Clinical Laboratory Core Facility at the 
UNC Medical School for hepatotoxicity studies.
2.6.4. In Vivo Anticancer Efficiency—Xenograft tumors were inoculated in the left 
flanks of male athymic nude mice (6–7 weeks old, 28–30 g; UNC Animal Services Core, 
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Chapel Hill, NC) by subcutaneous injection of 1 × 106 H460 or PC3 cells in 200 μL of a 1:1 
(by volume) mixture of serum-free RPMI-1640 (for H460 cells) or a 1:1 mixture of DMEM 
and Ham's F-12 medium/Matrigel solution. After 10 days (for the H460 xenograft tumor) or 
14 days (for the PC3 xenograft tumor), the mice were randomly distributed into 5 groups (5 
mice per group) for different treatments. Prior to treatment, all mice were ear-tagged, their 
initial tumor volumes (Vi) were measured by a caliper, and their average body weights were 
recorded. In treatment, all mice received a single tail-vein i.v. administration of either 200 
μL PBS (control group), drug-free (“empty”) Fol-targeted liposomes,# 0.8 mg/kg (half of the 
MTD) of small-molecule Zol, or 0.8 mg/kg (half of the MTD) of encapsulated Zol (from 
either non-targeted CaZol nMOFs or Fol-targeted CaZol nMOFs). Tumor volume was 
measured every 2 to 3 days with a caliper. Tumor volumes were calculated by measuring 
two perpendicular diameters with a caliper and using the formula V = 0.5 × a × b2, where a 
and b are the larger and smaller diameters, respectively. The initial tumor volume (Vi) for 
H460 and PC3 xenograft tumors was found to be 90 ± 7 and 83 ± 5 mm3, respectively. 
Tumor growth in the different treatment modalities was monitored until the large diameter 
increased to above 20 mm or the volume increased to above 50 times its initial volume, at 
which point the animal was euthanized by overdose of carbon dioxide. [N.B. # administered 
the same amount of lipid coating as in the Fol-targeted CaZol nMOFs; i.e., each mouse 
received i.v. administration of 200 μL of 245 μg/mL drug-free Fol-targeted liposomes.]
The average growth delay (AGD) and enhancement factor (EF) of each treatment group 
were defined and calculated according to a well-documented method [24, 25]. Briefly, AGD 
is the difference between the number of days it took the tumor in the treated group to grow 
to 40 times (for H460 tumor) or 30 times (for PC3 tumor) its initial volume and the time it 
took the tumor in the untreated control group (administered with PBS only) to reach the 
same size. The EF of drug-free Fol-targeted liposomes, non-targeted CaZol nMOFs, and 
Fol-targeted CaZol nMOFs is the ratio of the AGD of a particular treatment group to the 
AGD of the treatment group treated with small-molecule Zol.
2.6.5. Tumor Histology—Xenograft tumors were inoculated in the left flanks of male 
athymic nude mice (6–7 weeks old, 28–30 g; UNC Animal Services Core, Chapel Hill, NC) 
by subcutaneous injection of 1 × 106 H460 or PC3 cells in 200 μL of a 1:1 (by volume) 
mixture of serum-free RPMI-1640 (for H460 cells) or a 1:1 mixture of DMEM and Ham's 
F-12 medium/Matrigel solution. After 10 days (for the H460 xenograft tumor) or 14 days 
(for the PC3 xenograft tumor), the mice were randomly distributed into 16 groups (3 per 
group) for different treatments. In treatment, all mice received a single tail-vein i.v. 
administration of either 200 μLPBS (control group), drug-free (“empty”) Fol-targeted 
liposomes, 0.8 mg/kg (half of the MTD) of small-molecule Zol, or 0.8 mg/kg (half of the 
MTD) of encapsulated Zol (from either non-targeted CaZol nMOFs or Fol-targeted CaZol 
nMOFs). Tumor volume was measured every 2 to 3 days with a caliper.
Mice were euthanized by overdose of carbon dioxide 4 days after treatment. The tumors 
were collected and fixed in 4% neutral-buffered formalin for 2 days at 5 °C and then in 70% 
ethanol at 5 °C for another 2 days before being submitted to the Animal Histopathology 
Core Facility at UNC Medical School for sectioning. CD31, PCNA and caspase-3 
immunohistochemistry stains were performed using biological tissue automatic staining 
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machines in the Translational Pathology Lab at the UNC Medical School. Antibodies (CD31 
from Abcam, Cambridge, MA; PCNA from Cell Signaling Technology, Danvers, MA; 
caspase-3 from Cell Signaling Technology, Danvers, MA) were diluted to the desired 
concentrations in accordance with the manufacturers' instructions before 
immunohistochemistry stains were conducting using automatic staining machines. All 
immunohistochemistry stain slides used Hoechst stain to label the nuclei. CD-31-stained 
tumor sections were imaged using an Olympus IX 81 Inverted Wide-Field Light Microscope 
in the Microscopy Services Laboratory at the UNC Medical School. PCNA- and caspase-3-
stained tumor sections were imaged on a Zeiss 710 Spectral CLSM in the Microscopy 
Services Laboratory Core Facility at the UNC School of Medicine. Confocal fluorescent 
images were processed using ImageJ (NIH).
2.7. Statistical Analysis
Quantitative data were expressed as mean ± SEM. The analysis of variance was completed 
using a one-way ANOVA in Graph Pad Prism 6 software pack. p < 0.05 was considered 
statistically significant.
3. Results
3.1. Synthesis and Characterization of Fol-Targeted CaZol nMOFs
Fol-targeted CaZol nMOFs were synthesized in two steps (Fig. 1). Hydrophobic DOPA-
coated CaZol nMOFs were synthesized via the water-in-oil reverse microemulsion method 
(mFig. 1) [27]. Zol was converted to sodium zoledronate (Na4Zol) in situ prior to the 
preparation of a bisphosphonate-based microemulsion. Amphiphilic lipid DOPA was added 
to the bisphosphonate-based microemulsion as a surfactant to stabilize the microemulsion 
and the resulting nMOFs. Combining two microemulsions led to the formation of DOPA-
coated CaZol nMOFs due to inter-micellar exchange [27]. By adjusting the volume ratio of 
Igepal CO-520-based and Triton X-100-based oil phases, spherical DOPA-coated CaZol 
nMOFs varying from 10 to 100 nm in diameter were successfully synthesized (Fig. 2a). As 
shown in the transmission electron microscopy (TEM) images (Fig. 2a) and intensity-
average diameter (Dh) curves determined by the dynamic light scattering (DLS) technique 
(Fig. S1), the particle diameter and polydispersity of the DOPA-coated CaZol nMOFs 
increased with the Triton X-100-based oil volume fraction. Small nMOFs coexisted with 
larger but less spherical sub-100nm diameter nMOFs when the Igepal CO520-to-Triton 
X100 system volume ratio increased to above 1:2 (Fig. 2a). This is because the water-to-
surfactant molar ratio (Tables S1-S3) decreases with the inter-micellar exchange rate 
between two microemulsions. A higher exchange rate between micelles yields a larger 
number of smaller particles, but a slower exchange rate between micelles leads to the 
formation of fewer nuclei and results in fewer large particles and more polydisperse particles 
[28], Previous in vivo studies revealed that 50 to 100nm diameter monodisperse PEGylated 
lipid-coated CaP nMOFs are ideal for tumor uptake after systemic administration (i.e., i.v. 
administration) due to the enhancement permeability and retention (EPR) effect [27, 29]. 
Thus further studies focus on the DOPA-coated CaZol nMOFs prepared using a 1:1 v/v of 
Igepal CO-520/Triton X-100-based oil phases with a mean Dn of 57nm and a mean Dh of 
68nm (polydispersity index, PDI = 0.152).
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The selected hydrophobic DOPA-coated CaZol nMOFs were further characterized by 
complementary characterization techniques. An X-ray powder diffraction (XRD) study 
indicated the DOPA-coated CaZol nMOFs have a broad and diffused diffraction band 
centered at 2θ = 24° (Fig. S2). Thermal analysis revealed that the DOPA-coated CaZol 
nMOFs contained 12.7wt% of grafted DOPA (Fig. 2b). Elemental microanalysis via energy-
dispersive X-ray spectroscopy (EDS) revealed that the DOPA-coated CaZol nMOFs 
contained 11.7mol% Ca atoms and 8.5mol% P atoms (with a Ca/P molar ratio of 1.4); EDS 
revealed trace amount (0.5mol%) of Cl atoms, but no sodium atoms (Fig. 2c). The EDX and 
XRD studies indicated that the CaZol nMOFs are structurally similar to the amorphous 
hydroxyapatite in bone [30]. X-ray phototelectron spectroscopy (XPS) revealed that the 
surface of the CaZol nMOFs contain 2.1mol%, 6.7mol%, and 7.0mol% of N, Ca, and P 
atoms (Fig. 2d), respectively. The surface Ca/P molar ratio is approximately 1, suggesting 
that all phosphate groups from DOPA and Zol on the surface of the nMOFs have been 
deprotonated and coordinated to Ca2+. The high surface P/N molar ratio of 3.3 confirmed 
that nitrogen-free DOPA is on the surface of the nMOFs. Fourier transform infrared (FTIR) 
spectroscopy further confirmed the structure of the DOPA-coated CaZol nMOFs. The FTIR 
spectrum of the DOPA-coated CaZol nMOFs (Fig. 2e) showed a characteristic C-N 
stretching band at 1570 cm-1, a broad C=C stretching band at 1430 cm-1 due to the 
imidazole ring in Zol, a very strong and broad P=O stretching band at 1150 cm-1 and a P-O 
stretching band at 1070 cm-1 due to the deprotonated phosphate groups from DOPA and Zol 
[31]. In addition, a vibration band can be observed at 1740 cm-1, and it can be attributed to 
the C=O stretching from the ester group of the adsorbed DOPA. The drug loading of the 
DOPA-coated CaZol nMOFs was found to be 76wt %, using UV-visible spectroscopy 
method [17].
Polyethylene glycol (PEG) grafting density and surface lipids composition directly affect the 
colloidal stability, pharmacokinetics and biodistribution of PEGylated nMOFs [32, 33]. A 
Fol-targeted outer lipid leaflet composite of cholesterol (Chol), 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-
N-(methoxy(polyethylene glycol)-2000) (DSPE-PEG2000) and 1,2-distearoyl-sn-glycero-3-
phosphoethanolamine-N-(folate(polyethylene glycol)-2000) (DSPE-PEG200-Fol) was 
engineered onto the surface of the hydrophobic DOPA-coated CaZol nMOFs via the film 
rehydration method (Fig. 1 and Table S4). During the film rehydration process, the 
preassembled DOPA-based inner lipid aids the self-assembly of the outer lipid leaflet [27]. 
Small amphiphilic lipids (cholesterol and DOTAP) were added to engineer the outer lipid 
leaflet to fill the spaces between the larger PEGylated lipids, preventing their dissociation 
from the nMOFs [27, 33]. Non-targeted CaZol nMOFs were prepared using an identical 
method except pure non-targeted DSPE-PEG was used to prepare the PEGylated outer lipid 
coating. Fluorescent CaZol nMOFs were prepared using the same method except 7-
nitro-2,1,3-benzoxadiazol-4-yl (NBD)-labeled cholesterol was used instead of unlabeled 
cholesterol to prepare the outer lipid leaflet.
The successful fabrication of an outer Fol-targeted lipid leaflet was confirmed by TEM, 
DLS and the nanoparticle tracking analysis (NTA) methods. The TEM image of the Fol-
targeted CaZol nMOFs shows a characteristic core-shell structure (Fig. 3a) because lipids 
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have lower electron densities than CaZol. The diameter of the Fol-targeted CaZol nMOFs is 
significantly smaller than that of Fol-targeted liposomes prepared in the absence of DOPA-
coated CaZol nMOFs (Fig. 3a), suggesting the successful fabrication of asymmetric lipid-
coated CaZol nMOFs rather than the formation of the CaZol nMOF-encapsulated liposomes. 
DLS measurement (Fig. 3b) revealed that the mean Dh (and PDI) of the CaZol nMOFs 
increased from 68nm (PDI = 0.152) to 112nm (PDI = 0.186) upon fabrication of the outer 
lipid leaflet due to the presence of long hydrated PEG chains in the outer lipid leaflet. 
However the mean Dh of the nMOFs is significantly smaller than that of the Fol-targeted 
liposomes (mean Dh = 156 nm, PDI = 0.231; Fig. 3b). An NTA study indicated that the 
mean Dn of Fol-targeted CaZol nMOFs (115 nm, Fig. 3c) was significantly smaller than that 
of Fol-targeted liposomes prepared in the absence of DOTA-coated CaZol nMOFs. In 
addition, the NTA study indicated that the number of particle formed in the presence of 
DOPA-coated CaZol nMOFs was about twice that of the Fol-targeted liposomes (Fig. 3c). 
This indicates that the CaZol nMOFs are stabilized by an asymmetrical layer of lipids rather 
than encapsulating inside Fol-targeted liposomes. An aqueous electrophoresis study 
confirmed the presence of anionic DSPE-PEG-Fol on the surface of the CaZol nMOFs with 
a mean zeta potential (ζ) of -12.3 mV (in 1mM NaCl, pH 7) that was much lower than a 
near-zero mean ζ of + 0.2 mV (in methanol) recorded for the DOPA-coated CaZol nMOFs. 
Thermal analysis indicated the Fol-targeted CaZol nMOFs contained approximately 32.3 wt
% of outer lipid coating (Fig. 3d). A further UV-visible spectroscopic study revealed that the 
Fol-targeted CaZol nMOFs encapsulated 50.6 wt% Zol.
3.2. Cellular Uptake and Endosomal Escape of the Fol-Targeted CaZol nMOFs
Poor cellular uptake of long circulation PEGylated nMOFs caused a major challenge in 
nanomedicine [32, 34]. More than two-thirds of NSCLC, ovary and prostate tumors have 
overexpressed folate receptors [18]. The introduction of Fol ligands to the PEGylated CaZol 
nMOFs provides a unique opportunity to enhance the uptake of the CaZol nMOFs. A time-
dependent cellular uptake study indicated that H460 and PC3 cells took up about 22% and 
12%, respectively, of the incubated NBD-labeled Fol-targeted CaZol nMOFs after being 
incubated for 2h, respectively, which are about 5 to 6 times more than that of non-targeted 
CaZol nMOFs (Fig. S3a). The confocal fluorescence images of the H460 and PC3 cells (Fig. 
S3b) recorded 2h after being incubated with the NBD-labeled Fol-targeted CaZol nMOFs 
confirmed with fluorescence that the Fol-targeted nMOFs were rapidly internalized into the 
cancer cells and equally distributed in the cytoplasm.
Amorphous calcium phosphates (e.g., bones) have good chemical stability under 
physiological conditions but rapidly decompose at acidic environments [30]. A time-
dependent DLS study confirmed that the Fol-targeted CaZol nMOFs establish excellent 
colloidal stability and a high-ionic-strength physiological buffer under physiological 
conditions (37°C, pH 7; Fig. S4). A quantitative drug release study indicated that an 
insignificant amount (less than 5%) of the encapsulated Zol was released from the Fol-
targeted CaZol nMOFs under sink conditions at pH 7 (0.1M PBS, 37 °C; Fig. 4a). The rate 
of Zol release significantly increased when the pH of the PBS decreased to 5 (that of the 
endosome; Fig. 4a) due to the protonation of Zol (pKa1 = 5.9) [35]. At pH 5, approximately 
half of the encapsulated Zol was released from the particles in the first 3.5h and nearly all of 
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the encapsulated Zol was released in 24h (Fig. 4a) [36]. The pH-dependent study indicates 
the optimized nMOF preparation conditions and the strong chelating character of fully 
deprotonated Zol significantly improved the stability of the CaZol nMOFs at physiological 
pH (pH 7) and prolonged drug release in acidic environments (e.g., inside endosomes) 
compared with other calcium phosphate-based drug delivery systems [27, 29, 37, 38].
The intracellular Zol release mechanism was utilized in H460 and PC3 cells loaded with 
Fura-2. Fura-2 is an intracellular calcium indicator that, upon binding free intracellular Ca2+ 
and forming a stable Fura-2-Ca complex [29, 39], blue-shifts its emission band from 512 nm 
(upon excitation at 362 nm, in the “red” channel) to 505 nm (upon excitation at 335 nm, in 
the “green” channel). Figs. 4b and S5 show fluorescence images of Fura 2-loaded PC3 and 
H460 cells recorded before, 30min after, and 2h after incubation with Fol-targeted CaZol 
nMOFs containing 2μM Zol or just PBS (control). A time-dependent fluorescence imaging 
study indicated that the fluorescence intensity in the red channel progressively decrease, 
while the fluorescence intensity in the green channel progressively increased after being 
incubated with Fol-targeted CaZol nMOFs, indicating the formation of Fura-2-Ca complex. 
Quantitative image analyses (Fig. 4b and S5b) revealed that about 70% of intercellular 
Fura-2 was bound to the Ca2+ ions after incubation with the CaZol nMOFs for 30min and 
that nearly all Fura-2 became bound to Ca2+ ions after incubation with CaZol nMOFs for 2h 
(Fig. 4c). Conversely, incubating the Fura 2-labeled cells with PBS for 2h did not 
significantly change the fluorescence intensity at 512nm. This indicates that the CaZol 
nMOFs progressively release Ca2+ and Zol after entering the cancer cells via endocytosis. 
The released Ca2+ bound to the intercellular Fura-2 led to the formation of green emission 
Fura-2-Ca complex (Fig. 4c).
3.3. In Vitro Toxicity of Non-Targeted and Fol-Targeted CaZol nMOFs
The in vitro toxicities of small-molecule (“free”) Zol, empty (“drug-free”) Fol-targeted 
liposomes, and both non-targeted and Fol-targeted CaZol nMOFs in H460 and PC3 cell 
lines were first evaluated using a 3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) cell proliferation assay. A 
concentration-dependent study (Figs. 5a and 5b) indicated that the Fol-targeted CaZol 
nMOFs were more efficient than small molecule Zol at inhibiting the proliferation of H460 
and PC3 cell lines in culture. The half maximal inhibitory concentration (IC50, inhibition of 
cell growth by 50%) of the Fol-targeted CaZol nMOFs were found to be 2.3 μM 
(concentration of encapsulated Zol) in H460 and 1.7 μM in PC3 cell lines, which are 6 to 19 
times higher than the concentrations for small-molecule Zol (Figs. 5a and 5b). On the other 
hand, non-targeted CaZol nMOFs showed much lower cytotoxicity (IC50 > 50 μM) in both 
cell lines. This indicated that increased cellular uptake and prolonged drug release kinetics 
of the Fol-targeted CaZol nMOFs significantly improved the growth inhibition efficiency of 
Zol in both FR-overexpressing cell lines.
Caspase 3 antibody was used to quantify an early-stage programmed cell death (apoptosis) 
induced by the small-molecule and encapsulated Zol [40]. Figs. 5c and S6 show confocal 
fluorescence images of caspase 3 antibody-stained H460 and PC3 cells recorded 12h after 
treatment with PBS (control), 5 μM of small-molecule Zol, and NBD-labeled targeted and 
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non-targeted CaZol nMOFs containing 5 μM of encapsulated Zol for 2h. Both cell lines 
showed very low caspase 3 activities (red fluorescence) after incubation with PBS. The 
caspase 3 activities significantly increased after incubation with small-molecule Zol. 
Quantitative image analyses (Fig. 5c) indicated that the caspase 3 activities increased by 
about 100% in H460 cells and nearly 180% in PC3 cells after the in vitro treatment with the 
small-molecule Zol, as compared to the control groups that were incubated with PBS (Fig. 
S6). In vitro treatment with Fol-targeted CaZol nMOFs significantly increased the caspase 3 
activities by 230% and 300% in H460 and PC3 cell lines, respectively, compared the control 
groups. On the other hand, in vitro treatment with non-targeted CaZol nMOFs only 
increased the caspase 3 activities by 40 – 50% when compared to the corresponding control 
groups. The lower apoptotic activities recorded for the non-targeted CaZol nMOFs were due 
to the non-targeted nMOFs have relatively low cellular uptake when compared to Fol-
targeted nMOFs, as justified by the higher NBD fluorescence intensity recorded for the cells 
incubated with the Fol-targeted nMOFs (Fig. 5c). The in vitro toxicity study indicated that 
the Fol-targeted CaZol nMOFs were more efficient than the small-molecule Zol at inhibiting 
the growth and inducing the apoptosis of H460 and PC3 cells; this effect was likely due to 
the slow-drug release kinetics of the CaZol nMOFs.
3.4. Tumor Uptake, Biodistribution and Systemic Toxicity of Non-Targeted and Folate-
Targeted CaZol nMOFs
Tumor uptake and biodistribution of NBD-labeled non-targeted and Fol-targeted CaZol 
nMOFs were utilized in healthy athymic nude (Nu) mice and H460 xenograft tumor-bearing 
Nu mice via ex vivo fluorescence imaging technique. Samples from the tumor, heart, lung, 
and mononuclear phagocyte system (MPS, also known as the reticuloendothelial system, 
including the liver, kidney, and spleen) were collected 48h after tail vein i.v. administration 
of PBS (control), NBD-labeled non-targeted, and Fol-targeted CaZol nMOFs containing 1.6 
mg/kg (MTD of Zol in mouse) of encapsulated Zol for ex vivo imaging study (Figs. S7 - S9). 
Ex vivo image analyses (Fig. S10) revealed that about 82% of the i.v. administrated Fol-
targeted CaZol nMOFs were accumulated in the tumor, but that only about 52% of the non-
targeted CaZol nMOFs were accumulated in the tumor. The majority of the remaining 
administered CaZol nMOFs were accumulated in the liver (12% of Fol-targeted CaZol 
nMOFs and about 30% of the non-targeted CaZol nMOFs), and less than 10% of the 
administrated Fol-targeted CaZol nMOFs and 16% of the non-targeted CaZol nMOFs were 
accumulated in the other organs in the MPS, heart and lung. On the other hand, 
approximately 60% and 20% of the administered Fol-targeted CaZol nMOFs were 
accumulated in the liver and kidney, respectively, in healthy Nu mice. Up to 25% of the Fol-
targeted CaZol nMOFs were found in the heart and lung of healthy tumor-free mice, 
suggesting that a significant amount of the PEGylated CaZol nMOFs were remained in the 
circulation system due to the EPR effect. The biodistribution study indicated that the Fol-
targeted CaZol nMOFs are more efficient than non-targeted CaZol nMOFs for tumor uptake 
and to reduce the non-specific accumulation of nMOFs in the liver and kidney. However, 
the low accumulation of both NBD-labeled CaZol nMOFs in the liver and kidney could be 
caused by the high absorption and scattering characters of both MPS organs [41], which is 
an intrinsic limitation of using ex vivo fluorescence imaging technique to elevate 
biodistribution of nanomaterials.
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Zol is a third-generation bisphosphonate that has fewer side effects than the first two 
generations bisphosphonates. Common short-term side effects associated with Zol include 
“flu-like” symptoms (caused by activation of γδ T cells) [42, 43], hypocalcaemia [44], and 
renal failure [45]. Table S5 summarizes the hematologic toxicity, nephrotoxicity and 
hepatotoxicity parameters, and the plasma calcium level recorded for the healthy tumor-free 
CD1 mice 4 days after tail-vein i.v. administration of PBS, drug-free Fol-targeted liposomes, 
and a therapeutic dose (1.6 mg/kg, maximum tolerated dose (MTD) of Zol in mice) of small 
molecule or encapsulated Zol. The key toxicity parameters recorded after i.v. administration 
of small molecule and encapsulated Zol were within the documented normal ranges for 
healthy CD1 mice except that the monocyte level of the CD1 mice administered with small-
molecule Zol was above the normal range due to the activation of γδ T cells [43]. Although 
the biodistribution study revealed that the majority of the administered CaZol nMOFs were 
accumulated in the liver and kidney of healthy tumor-free mice, a therapeutic dose of CaZol 
nMOFs showed insignificant hepatotoxicity and nephrotoxicity in healthy CD1 mice.
3.5. Tumor Growth Inhibition Efficiencies of Small Molecule Zol, Non-Targeted and Fol-
Targeted CaZol nMOFs in the H460 and PC3 Xenograft Tumor Models
In vivo chemotherapy was performed in mouse H460 and PC3 tumor xenograft models. 
Tumor-bearing Nu mice were given a single sub-therapeutic dose of chemotherapy, either 
i.v. administration of PBS (as a control), drug-free Fol-targeted liposomes or 0.8 mg/kg (half 
of the MTD of Zol in mice) of small molecule or encapsulated Zol. This enabled precise 
quantification of the therapeutic effects of each treatment without eradication of tumor in all 
experimental arms. Figs. 6a(i) and 6b(ii) show tumor-growth delay curves recorded 10 and 
14 days after tumor inoculation for H460 and PC3 xenograft tumor-bearing mice that 
received different treatments. The administration of drug-free Fol-targeted liposomes did not 
delay tumor growth in both cell lines compared with the control group, which was 
administrated with PBS (p > 0.05 versus control group in both cell lines). The administration 
of small-molecule Zol significantly delayed the growth of H460 and PC3 tumors (p = 0.01 – 
0.02 versus the corresponding control group) by an average of 8 and 11 days (Figs. 6a(ii) 
and 6b(ii)), respectively. The administration of Fol-targeted CaZol nMOFs further delayed 
the growth of H460 and PC3 xenograft tumors by 15 and 20 days (Fig. 6a(ii) and 6b(ii)), 
respectively, compared with the control group (p < 0.01) and the treatment group 
administered with small-molecule Zol (p = 0.02 for H460 tumor, and p = 0.03 for PC3 
tumor). On the other hand, the administration of non-targeted CaZol nMOFs only slightly 
delayed tumor growth compared with the control group that was administrated with PBS (p 
= 0.04), and the tumor-growth delay efficiency was significantly weaker for non-targeted 
CaZol nMOFs than for small-molecule Zol (p = 0.03 for H460 cell line, p = 0.06 for PC3 
cell line). Quantitative tumor growth delay analyses (Fig. 6c) indicated that the Fol-targeted 
CaZol nMOFs significantly enhance the antitumor activity of Zol by 83 – 85% in in both 
types of xenograft tumor with overexpressed FR. Conversely, the administration of non-
targeted CaZol nMOFs reduce the antitumor activity of Zol by 60 – 61% in both xenograft 
tumor models due to poor tumor uptake, as justified by the in vivo biodistribution study.
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3.6. Histopathological Insight
Further histopathological studies were performed to gain insight into the anticacner activities 
of the small-molecule Zol and Fol-targeted CaZol nMOFs. Representative H460 and PC3 
xenograft tumors (3 per group) were removed 4 days after chemotherapy to investigate the 
underlying therapeutic effects of different treatments.
A previous in vitro study found that Zol effectively inhibited basic fibroblast growth factor 
(bFGF) and vascular endothelial growth factor (VEGF), which are the key growth factors 
that control the growth of blood vessels and thus delaying tumor growth [11, 12]. The CD31 
immunochemical stain via the anit-CD31 antibody was used to label vascular endothelial 
cells to quantify blood vessels in the tumor [46], Fig. 7a shows representative optical 
micrographs of CD31 antibody-stained H460 and PC3 tumor sections. Both untreated tumor 
sections have an average of 20 ± 2 blood vessels per image. The administration of small 
molecule Zol reduced the number of blood vessels by about 50% in both xenograft tumor 
models. The antiangiogenic effect of small-molecule Zol in the H460 and PC3 tumors was 
comparable to that observed in the previous ex vivo study. The administration of Fol-
targeted CaZol nMOFs effectively reduced the number of blood vessels to 6 ± 1 and 4 ± 1 
vessels per image in H460 and PC3 tumor sections, respectively. Conversely, the 
administration of non-targeted CaZol nMOFs showed very weak antiangiogenic effect in 
both types of xenograft tumors. The improved antiangiogenic effect observed in the tumor 
treated with Fol-targeted CaZol nMOFs can be explained by the increased Zol uptake and 
slower drug release mechanism of the Fol-targeted CaZol nMOFs.
A proliferation cell nuclear antigen (PCNA) immunochemical stain via the anti-PCNA 
antibody was used to quantify the number of active proliferating cancer cells in tumor 
sections after received different Zol treatments [47]. As shown in Fig. 7b, the number of 
PCNA-positive nuclei (red fluorescence) was significantly reduced from 88 ± 3% and 81 ± 
4% to 20 ± 5% and 27 ± 4% in H460 and PC3 tumors, respectively, upon treatment with 
small-molecule Zol. This indicated that small-molecule Zol effectively inhibited the 
proliferation of H460 and PC3 cancer cells. This is consistent with the in vitro cell 
proliferation study. Treatment with Fol-targeted CaZol nMOFs almost completely inhibited 
cell proliferation in both types of xenograft tumors, as less than 10% of the nuclei in the 
tumor treated with Fol-targeted CaZol nMOFs were found to be positive for PCNA. This is 
because most of the i.v. administrated Fol-targeted CaZol nMOFs had accumulated in the 
tumor and because the prolonged drug release kinetics improved the inhibition efficiency. 
On the other hand, the administration of non-targeted CaZol nMOFs only slightly reduced 
the number of PCNA positive nuclei to 60 ± 5% and 67 ± 2% in H460 and PC3 tumors, 
respectively, because fewer CaZol nMOFs were accumulated in the tumor as indicated by 
the biodistribution study.
The degree of early-stage programmed cell-death in the xenograft tumors were quantified 
using caspase 3 antibody [40]. Fig. 7c shows confocal fluorescence images of representative 
caspase 3 antibody-stained (red fluorescence) H460 and PC3 tumor sections. The caspase 3 
activities of H460 and PC3 tumor increased by 300 ± 45% and 155 ± 23%, respectively, 
compared with the control group after being treated with small-molecule Zol. This indicated 
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that small-molecule Zol directly induced apoptosis in both tumors, which is consistent with 
the in vitro toxicity study. The administration of Fol-targeted CaZol nMOFs significantly 
increased the caspase 3 activities by 560 ± 27% and 403 ± 45% in H460 and PC3 tumors, 
respectively. On the other hand, the administration of non-targeted CaZol nMOFs only 
slightly increased the caspase 3 activities (by 105 ± 27% and 45 ± 12% in H460 and PC3 
tumors, respectively). This indicates the tumor uptake of the CaZol nMOFs directly affected 
the therapeutic efficiency of the encapsulated Zol.
4. Discussion
In this study, we reported the fabrication of a new bioresorbable Fol-targeted CaZol nMOFs 
for the therapeutic delivery of Zol to FR-overexpressing tumors. Near-monodispersed 
sub-100 nm diameter asymmetric lipid-bilayer coated CaZol nMOFs have been successfully 
synthesized using an optimized stepwise synthesis method: the fabrication of hydrophobic 
DOPA-coated CaZol nMOFs via the water-in-oil microemulsion method followed by the 
fabrication of an active-targeted outer lipid leaflet coating via the film rehydration method. 
The Fol-targeted CaZol nMOFs encapsulated about 50.6 wt% of Zol, which is about 7 times 
higher than that of Zol-encapsulated liposomes [15], The optimized outer lipid leaflet 
coating method and the preassembled of the inner DOPA-based lipid leaflet allowed us to 
increase the PEGylated lipid compositions in the outer lipid leaflet from 5mol% (in normal 
clinical-use liposomes) [48] to 20 mol%. This not only improves the colloidal and chemical 
stabilities of the CaZol nMOFs in physiological environments, but also increases the nMOF 
uptake in FR-overexpressed cancer cells. An in vitro cellular uptake study indicated that the 
H460 and PC3 cells took up approximately 20 to 30% of the Fol-targeted CaZol nMOFs 
within a short incubation period (2h) but that both cell lines took up less than 5% of the 
administered non-targeted CaZol nMOFs under identical conditions. A further ex vivo 
biodistribution study in H460 tumor xenograft mice indicated the folate-receptor 
overexpressed tumor took up about 80% of the i.v. administrated fluorescent-label Fol-
targeted CaZol nMOFs, which is significantly higher than that of 14% recorded for Zol-
encapsulated liposomes in xenograft tumor model [16].
Drug release kinetics directly affect the therapeutic efficiency and symmetric toxicity of the 
encapsulated drug [49]. A “burst” release of an encapsulated drug in mildly acidic 
conditions is one of the major limitations of most calcium phosphate and calcium carbonate-
based drug delivery systems, which often reduce the therapeutic efficiency of the 
encapsulated drug [27, 29, 50]. In contrast to the reported lipid-caoted calcium 
monophosphate nanoparticles, the new Fol-targeted CaZol nMOFs control the release of the 
encapsulated Zol at mildly acidic (pH 5) conditions with a first ordered drug release half-life 
of 3.5h. The prolonging of the drug release kinetics is due to an optimized nMOF 
preparation conditions and strong chelating character of fully deprotonated bisphosphonate. 
An intercellular drug release study in Fura-2-loaded H460 and PC3 cells indicated that the 
CaZol nMOFs gradually decomposed and controlled the release of Ca2+ and Zol from the 
acidic endosomes after entering cancer cells via endocytosis (Fig. 8). The controlled Ca2+ 
release allows the plasma membrane Ca2+ ATPase (PMCA) in the cell membrane to 
regulate the intercellular Ca2+ level by pumping excess Ca2+ from the cytoplasm, preventing 
Ca2+-induced apoptosis or necrosis [51]. Due to the improved cellular uptake and prolonged 
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drug release kinetics, the Fol-targeted CaZol nMOFs were found to be more efficient than 
small molecule Zol in inhibiting cell proliferation, inducing apoptosis at 2- to 7-fold higher 
rates in H460 and PC3 cell lines, which is significantly more toxic than Zol-encapsulated 
liposomes [15]. On the other hand, non-targeted CaZol nMOFs showed very low in vitro 
toxicity due to poor cellular uptake. The encapsulation of Zol not only increased the in vitro 
toxicity, but also reduced the symmetric toxicities of small-molecule Zol, (e.g., non-specific 
activation of T cells as utilized in healthy CD1 mice). In addition, the side effects of the Fol-
targeted CaZol nMOFs are much weaker than that of Zol-conjugated liposomes [16].
In vivo studies demonstrated that small molecule Zol delayed the growth of fast-growing 
H460 and slow-growing PC3 xenograft tumors. The observed direct antitumor activities 
were likely due to the inhibition of bFGH, VEGF and FPPS in the mevalonate pathway 
[1-9]. In vivo treatment with a single therapeutic dose of Fol-targeted CaZol nMOFs 
effectively inhibited the growth of both xenograft tumors. Quantitative tumor growth 
delayed analyses indicated the administration of Fol-targeted CaZol nMOFs improved the 
therapeutic efficiencies of Zol by 83 to 85%. The improvement can be explained by the 
improved tumor uptake of the Fol-targeted CaZol nMOFs and the prolonged drug release 
kinetics of the CaZol nMOFs. On the other hand, the antitumor activities of the non-targeted 
CaZol nMOFs were significantly weaker than small-molecule Zol and Fol-targeted CaZol 
nMOFs due to the poor cellular uptake of the non-targeted nMOFs. In contrast to the 
conventional drug delivery systems where non-covalently encapsulated drug slowly release 
in the extracellular matrix [34], the chemically stable CaZol nMOFs release insignificant 
amount of encapsulated Zol in the slightly acidic extracellular tumor microenvironment (pH 
6.5 – 6.9) [52], as indicated in the in vitro drug release study. In addition, previous time-
dependent in vivo tumor uptake study found that sub-100 nm diameter non-targeted 
PEGylated nMOFs do not retain in the extracellular tumor miroenvironments very well [33], 
with about 50% of the initially accumulated nMOFs retained in the tumor 48h after i.v. 
administration. Further histopathological studies confirmed that the Fol-targeted CaZol 
NMOFs were more effective than small-molecule Zol at normalizing tissue 
microenvironments (e.g. inhibition of blood vessels growth), inhibiting cell proliferation and 
inducing apoptosis in both xenograft tumor models, which is consistent with the direct 
anticancer and antiangiogenesis effects observed in this and previous in vitro studies. The 
inhibition of FPPS suspended the conversion of GPP into FPP (Fig. 8). This caused 
accumulation of unprenylated proteins, including IPP and apoptotic ATP analog (Apppl), 
which triggers apoptosis of cancer cells (see Fig. 8). In addition, the reduction of FPP 
downregulates Ras farnesylation, and Rho, Rac and Rab geranylation (Fig. 8), which inhibit 
the activation of the cell signaling molecules that are responsible for the proliferation, 
adhesion and migration of cancer and endothelial cells [1-9]. Furthermore, moderate 
concentrations (sub-10 μM) of Zol inhibit bFGF and VEGF [11,12], which are responsible 
for blood vessel growth (Fig. 8). The inhibition of endothelial cells, bFGF, and VEGF 
account for the antiangiogenesis effect observed in H460 and PC3 xenograft tumor sections 
[11, 12]. The histopathological study further confirmed that active targeted was essential to 
improving the tumor uptake of the CaZol nMOFs, and thus enhancing the therapeutic 
efficiency of the encapsulated Zol.
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5. Conclusion
In summary, we engineered a new bioresorbable Fol-targeted CaZol nMOFs for therapeutic 
delivery of Zol to FR-overexpressed tumors. The new active-targeted CaZol nMOFs 
encapsulated more Zol than existing drug delivery systems (e.g., liposomes) and established 
excellent chemical and colloidal stability under physiological conditions (0.1 M PBS, pH 7). 
The Fol-targeted lipid coating facilitates the endocytosis of the CaZol nMOFs in FR-
overexpressed cancer cells, allowing the nMOFs to control the release of encapsulated Zol 
in mildly acidic endosomes. Due to the super cellular uptake and prolonged drug release 
kinetics, the Fol-targeted CaZol nMOFs showed higher efficiency than small molecule Zol 
at inhibiting cell proliferation and inducing apoptosis in FR-overexpressing H460 and PC3 
cancer cells in vitro. An in vivo biodistribution study indicated that over 80% of i.v. 
administrated Fol-targeted CaZol nMOFs accumulated in the H460 xenograft tumor 48h 
after administration, due to the EPR effect from the PEGylated lipid coating and the active-
targeted effect from the Fol ligand. Quantitative in vivo antitumor activity studies in H460 
and PC3 xenograft tumor-bearing mice indicated the Fol-targeted CaZol nMOFs but not 
non-targeted CaZol nMOFs improved the direct antitumor efficiencies of Zol by 
approximately 80%. Further histopathology study indicated the Fol-targeted CaZol nMOFs 
were more efficient than the small-molecule Zol to normalizing tissue microenvironments, 
inhibiting cell proliferation, and inducing cell apoptosis in both FR-overexpressing H460 
and PC3 xenograft tumors. Therefore, these preclinical studies show that Fol-targeted CaZol 
nMOFs may be promising to develop as a FR-targeting anti-neoplastic agent.
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Fig. 1. 
Synthesis of Fol-targeted CaZol nMOFs. Hydrophobic DOPA-coated CaZol nMOFs were 
prepared via the water-in-oil microemulsion method. The hydrophilic Fol-targeted lipid-
coating was fabricated onto the hydrophobic DOPA-coated CaZol nMOFs via the film 
rehydration method. Table S4 shows the chemical structures of lipids in the inner and outer 
lipid leaflets of the Fol-targeted CaZol nMOFs.
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Fig. 2. 
Characterization of hydrophobic DOPA-coated CaZol nMOFs. (a) TEM images recorded for 
DOPA-coated CaZol nMOFs prepared using oils with different volume ratios of Igepal-
based and Triton-based oil systems. The Igepal-based oil system is composed of a 71:29 v/v 
of cyclohexane and Igepal CO-520. The Triton-based oil is composed of a 75:15:10 v/v/v of 
cyclohexane, Triton X-100, and 1-hexanol. The diameters of the CaZol nMOFs increase as 
the volume fraction of the Triton-based oil phase increases. The pink arrow highlights the 
small, irregularly shaped CaZol nMOFs. (b) TGA curves recorded for (i) DOPA, (ii) CaZol 
bulk powder, and (iii) DOPA-coated CaZol nMOFs. It was calculated that the DOPA-coated 
CaZol nMOFs contained 12.7wt% of garfted DOPA.‡ (c) An energy-dispersive X-ray 
spectrum recorded for DOPA-coated CaZol nMOFs. The inset table summarizes the bulk 
composition of the DOPA-coated CaZol nMOFs. (d) (i) XPS survey spectrum recorded for 
DOPA-coated CaZol nMOFs. The inset table summarizes the surface composition of the 
DOPA-coated nMOFs. (N.B. # the C and N bands are affected by the background of carbon 
tape used to hold the powders for the EDS study.) (ii) P 2p core-line spectrum recorded for 
the DOPA-coated CaZol nMOFs. The strong P 2p band can be attributed to the P atoms in 
the DOPA (stabilizer) and Zol (core of the nMOF). (iii) N 1s core-line spectrum recorded 
for the DOPA-coated CaZol nMOFs. The strong N 1s band can be attributed to the N atom 
in Zol's imidazole ring. (e) Assigned ATR FT-IR spectra recorded for (i) DOPA, (ii) 
deprotonated Zol (Na4Zol), and (iii) dried DOPA-coated CaZol nMOFs. [N.B. ‡ By 
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comparing the wt% of bulk CaZol and DOPA-coated CaZol nMOFs remained at 800°C, the 
amount of grafted DOPA in the DOPA-coated CaZol nMOFs = 100wt% – (wt% of the 
DOPA-coated CaZol nMOFs remained at 800°C)/(wt% of the bulk CaZol MOFs remained 
at 800°C) = 100wt% - (100.0wt% - 41.4wt%)/(100.0wt% - 32.9wt%) = 12.7 wt %]
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Fig. 3. 
Characterization of Fol-targeted PEGylated CaZol nMOFs. (a) TEM images recorded for (i) 
asymmetric lipid-coated Fol-targeted CaZol nMOFs and (ii) Fol-targeted liposomes 
prepared in the absence of DOPA-coated CaZol nMOFs. (b) Number-average diameter (Dn) 
distribution curves recorded for 5 μg/mL of (i) Fol-targeted CaZol nMOFs and (ii) Fol-
targeted liposomes prepared in the absence DOPA-coated CaZol nMOFs, as determined by 
the NTA method. Calculations showed that 5 μg/mL of the Fol-targeted nMOFs contain 5.2 
× 109 particles per mL and that 5 μg/mL of Fol-targeted liposomes contain 2.3 × 109 
particles per mL. Thus, the average weight of each Fol-targeted CaZol nMOF is 9.6 × 10-16 
g, and the average weight of each Fol-targeted liposome is 2.2 × 10-15 g. (c) Intensity-
average diameter (Dh) distribution curves recorded for (i) DOPA-coated CaZol nMOFs 
(dispersed in chloroform), (ii) Fol-targeted CaZol nMOFs, and (iii) Fol-targeted liposomes 
prepared in the absence of DOPA-coated CaZol nMOFs. (d) TGA curves recorded for (i) 
DOPA-coated CaZol nMOFs, (ii) DOTAP, (iii) cholesterol (Chol), (iv) DSPE-PEG, and (v) 
asymmetric, lipid-coated Fol-targeted CaZol nMOFs. It was calculated that the Fol-targeted 
CaZol nMOFs contained 32.3wt% of outer lipid coating.‡ [N.B. ‡ By comparing the wt% of 
DOPA-coated CaZol NPs and Fol-targeted CaZol nMOFs remained at 800°C, the amount of 
outer Fol-targeted lipid coating in the Fol-targted CaZol nMOF = 100wt% – (wt% of the 
Fol-targeted CaZol nMOFs remained at 800°C)/(wt% of the Fol the DOPA-coated CaZol 
nMOFs remained at 800°C) = 100wt% – (100.0wt% -60.3wt%)/(100.0wt% - 41.4wt%) = 
32.3wt%]
Au et al. Page 27
Biomaterials. Author manuscript; available in PMC 2017 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Fig. 4. 
Drug-release mechanism of Fol-targeted CaZol nMOFs. (a) In vitro drug-release kinetics of 
Fol-targeted CaZol nMOFs under sink conditions at pH 7.0 and pH 5.0 (in 0.1 M PBS at 37 
°C). Insert shows chemical structure of deprotonated Zol in CaZol nMOF. pKa of Zol = 5.9, 
8.3[35]. (b) Fluorescence images of Fura-2-loaded PC3 cells recorded (i) immediately, (ii) 
30 min, and (iii) 2 h after being incubated with 1 μM of Fol-targeted CaZol nMOFs; and 
recorded (iv) after incubation in 0.1 M PBS for 2 h (control) at an excitation wavelength of 
362 nm and an emission wavelength of 512 nm (the red channel, which is proportional to the 
concentration of free Fura-2) and an excitation wavelength of 362 nm and an emission 
wavelength of 512 nm (the green channel, which is proportional to the concentration of the 
Fura-2-Ca complex due to the Ca2+ released from the CaZol nMOFs). Bar chart 
summarizing the ratio of fluorescence intensities at 478 nm and 505 nm, which is 
proportional to the concentration of unbound Fura-2. (Fig. S3 shows the intracellular release 
of free Ca2+ ions from Fol-targeted CaZol nMOFs in the H460 lung-cancer cell line.) (c) 
Cartoon shows the cellular uptake, intercellular Ca2+ and Zol release mechanism of CaZol 
nMOFs and the formation of the Fura-2-Ca complex.
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Fig. 5. 
In vitro toxicities of small-molecule (“free”) Zol, non-targeted and Fol-targeted CaZol 
nMOFs. Cell viabilities of (a) H460 and (b) PC3 cells after treatment with different 
concentrations of (i) drug-free Fol-targeted liposomes, (ii) small-molecule Zol, (iii) non-
targeted CaZol nMOFs, and (iv) Fol-targeted CaZol nMOFs, as determined by a MTS cell-
proliferation assay. (c) Early-stage apoptosis in H460 and PC3 cells. Confocal fluorescence 
images of (i) H460 and (ii) PC3 cells recorded after treatment with 5 μM of free Zol, NBD-
labeled non-targeted CaZol nMOFs and Fol-targeted CaZol nMOFs containing 5 μM of 
encapsulated Zol for 2 h and incubation under physiological conditions for another 12 h 
before staining with Rhod-labeled caspase 3 (CASP 3, which is red fluorescent and an early-
stage apoptosis marker). Fig. S6 shows confocal fluorescence images recorded for H460 and 
PC3 cells treated with 0.1 M PBS (control). (N.B. # containing the same amount of lipid 
coating as in the Fol-targeted CaZol nMOFs; e.g., 1 μM encapsulated Zol = 0.27 μg/mL of 
Fol-targeted CaZol nMOFs because Zol makes up 50.6 wt% of each Fol-targeted CaZol 
nMOF; the weight of a Fol-targeted CaZol nMOF is 9.6 × 10-16 g, and the weight of each 
drug-free Fol-targeted liposome is 2.2 × 10-15 g; and 1 μM of encapsulated Zol in a CaZol 
nMOF contains 1.2 μg/mL of Fol-targeted lipid coating; * p < 0.05, which is statistically 
significant.)
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Fig. 6. In vivo
antitumor efficiencies of drug-free Fol-targeted liposomes, small-molecule Zol, and non-
targeted and Fol-targeted CaZol nMOFs. (a)(i) Tumor growth-delay curves and (ii) Kaplan-
Meier survival curves of H460 lung xenograft tumor-bearing mice after a single i.v. 
administration of PBS, drug-free Fol-targeted liposomes,# or 0.8 mg/kg (half of the MTD of 
Zol in mice) of small-molecule or encapsulated Zol. (b)(i) Tumor growth-delay curves and 
(ii) Kaplan-Meier survival curves of PC3 prostate xenograft tumor-bearing mice after a 
single i.v. administration of PBS, drug-free Fol-targeted liposomes, or 0.8 mg/kg (half of the 
MTD of Zol in mice) of small-molecule or encapsulated Zol. (c) Table comparing in vivo 
antitumor efficiencies of small-molecule and encapsulated Zol. (N.B. # containing the same 
amount of lipid coating as the Fol-targeted CaZol nMOFs; i.e., each 29–30 g mouse received 
IV administration of 200 μL of 245μg/mL of drug-free Fol-targeted liposomes; n.s. = 
statistically insignificant; * p < 0.05, which is statistically significant.)
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Fig. 7. 
Histology of H460 and PC3 tumor sections after received different Zol treatments. (a) 
CD31-stained H460 and PC3 tumor sections after treated with PBS, small molecule (“free”) 
Zol, non-targeted and Fol-targeted CaZol nMOFs. The CD31 antibody (brown) labeled the 
vascular endothelial cells. (b) PCNA- and (c) caspase 3-stained H460 and PC3 tumor 
sections after treatment with PBS, small-molecule (“free”) Zol, or non-targeted and Fol-
targeted CaZol nMOFs. The PCNA antibody (red fluorescence) indicates a nucleus 
undergoing cell proliferation. The Caspase 3 antibody (red fluorescence) indicates cells 
undergoing early-stage apoptosis (programmed cell death). (N.B. the nuclei in all tumor 
sections were co-stained with DAPI (blue fluorescence); * p < 0.05, which is statistically 
significant.)
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Fig. 8. 
Direct anticancer activity of Fol-targeted CaZol nMOFs against a Fol-receptor-
overexpressed cancer cell. Active-targeted PEGylated CaZol nMOFs bind to the Fol 
receptor in Fol-receptor-overexpressed cancer cells and enter the cells via endocytosis. The 
(partial) protonation of CaZol nMOFs in the mildly acidic endosomes (pH ≈ 5) triggers the 
release of therapeutic, active Zol. Zol inversely inhibits farnesyl diphosphate synthase 
(FPPS), basic fibroblast growth factor (bFGF) and vascular endothelial growth factor 
(vEGF), which in turn inhibit cancer-cell proliferation, trigger apoptosis, and inhibit blood-
vessel growth. (N.B. HMG-CoA = 3-hydroxy-3-methylglutaryl-coenzyme A; IPP = 
isopentenyl pyrophosphate; GPP = geranyl pyrophosphate; FPP = farnesyl pyrophosphate; 
GGPP = geranylgeranyl pyrophosphate)
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